Skip to main content

liraglutide

Generic: LIRAGLUTIDE·Brand: LIRAGLUTIDE, SAXENDA, Saxenda, VICTOZA

liraglutide: 6 clinical trials tracked.

liraglutide evidence translation

What we can confirm

6 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about liraglutide, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 1 study sponsors
Clinical Trials (6)

Investigation of the Effect of Fasting Duration and Temporary Withholding of GLP-1 RAs on Retained Gastric Contents in Participants Treated With s.c. Liraglutide, Oral Semaglutide or s.c. Semaglutide

NCT07225816·Phase 1·NVO
Recruiting

Primary endpoint: Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal after dosing of subcutaneous (s.c.) liraglutide once daily (Yes/No)

Interventionalopen71 targetStarted 2025-11Completion 2027-011 site · United StatesNovo Nordisk A/S

Multicentre, Single-arm, Non-interventional Regulatory Post- Marketing Surveillance (rPMS) Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.

NCT06283641·NVO
Completed

Primary endpoint: Incidence of adverse events (AEs) by preferred term (PT)

Observational300 enrolledStarted 2024-04Completion 2025-0115 sites · TaiwanNovo Nordisk A/S

Effectiveness of Semaglutide 2.4 mg vs. Commercially Available Medications for Chronic Weight Management in Participants With Obesity in a Multi-employer Setting in The US - a Pragmatic Clinical Study

NCT05579249·Phase 4·NVO
Completed

Primary endpoint: Number of Participants Who Achieved Greater Than or Equal to (≥) 10.0 Percent (%) Body Weight Reduction (Yes/no)

InterventionalRandomizedopen500 enrolledStarted 2023-01Completion 2024-111 site · United StatesNovo Nordisk A/S

Effects of Liraglutide, Empagliflozin and Linagliptin on Mild Cognitive Impairment Remission in Type 2 Diabetes (LIGHT-MCI): A Multicentre, Randomised Controlled Trial With An Extension Phase

NCT05313529·N/A
Active, not recruiting

Primary endpoint: Mild cognitive impairment (MCI) remission rate

InterventionalRandomizedopen396 targetStarted 2022-10Completion 2026-075 sites · ChinaThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Effect and Safety of Liraglutide 3.0 mg on Weight Management in Children With Obesity Aged 6 to Below 12 Years: 56-week, Double-blind, Randomised, Placebo-controlled Trial

NCT04775082·Phase 3·NVO
Active, not recruiting

Primary endpoint: Relative change in BMI (Body mass index)

InterventionalRandomizedquadruple78 targetStarted 2021-03Completion 2027-0232 sites · Belgium, India, Israel, Malaysia…Novo Nordisk A/S

Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican Patients

NCT02773355·NVO
Completed

Primary endpoint: Frequency of pancreatitis

Observational27 enrolledStarted 2016-05Completion 2022-0214 sites · MexicoNovo Nordisk A/S